{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014144","form_type":"8-K","ticker":"ADGM","cik":"0002006986","company_name":"Adagio Medical Holdings, Inc.","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.556322+00:00","generated_at":"2026-05-30T07:06:08.152074+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Adagio Medical announces restatement of FY2023, Q1 and Q2 2024 financials; material weakness identified","bullets":["Audit committee concluded FY2023 audited and Q1/Q2 2024 unaudited statements should not be relied upon due to accrued interest misstatement.","Error found during Q3 2024 prep; overstatement of accrued interest on convertible notes and other liabilities.","Company will restate financials via Amendment No. 2 to the Business Combination Super 8-K.","Material weakness in internal control over financial reporting regarding review of third-party valuation reports for debt/equity.","Remediation plan includes additional review of valuation reports, manual journal entries, and enhanced oversight controls."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014144","json":"https://secwatch.observer/filing/0001558370-24-014144.json","markdown":"https://secwatch.observer/filing/0001558370-24-014144.md","text":"https://secwatch.observer/filing/0001558370-24-014144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006986/000155837024014144/0001558370-24-014144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006986/000155837024014144/adgm-20241101x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:06:08.152074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36ebe0711a3476a8ce00aa488c48e0156b66233d","claim":"Adagio Medical Holdings, Inc. reported that prior financial statements should not be relied upon.","evidence_excerpt":"024 and 2023, which were reported in an amendment to the Business Combination Super 8-K on Form 8-K/A filed with the SEC on August 14, 2024 (the periods referenced in clause (i), (ii), and (iii), the “Relevant Periods”) should no longer be relied upon with respect to the error described below and should be restated. In addition, any earnings releases or other communications relating to the Relevant Periods should no longer be relied upon with respect to the error described below. ​ As the Company previously reported on the Business Combination Super 8-K, on July 31, 2024 (the “Closing Date”), the Company consummated a business combination pursuant to the terms of the Business Combination Ag","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2006986/000155837024014144/0001558370-24-014144-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"non reliance"},{"label":"Auditor","value":"WithumSmith+Brown, PC"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}